Targeting KIT by frameshifting mRNA transcripts as a therapeutic strategy for aggressive mast cell neoplasm
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
The aim is to create new genomics solutions that could combat cancer and advance market access
TSC causes epilepsy in up to 85 % of patients, and up to 60 % of those patients do not respond to standard anti-seizure medicines
Preclinical and early human data indicate BriLife may confer enhanced immunity against Delta variant
All India Institute of Ayurveda hosts ministers and showcase their achievements
Phase II trial will evaluate the safety and efficacy of ASC40 in patients with moderate to severe acne
Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series
This work has been published in the journal ‘ACS applied materials and interface’
Subscribe To Our Newsletter & Stay Updated
